Literature DB >> 17342750

DNA copy number alterations in prostate cancers: a combined analysis of published CGH studies.

Jishan Sun1, Wennuan Liu, Tamara S Adams, Jielin Sun, Xingnan Li, Aubrey R Turner, Baoli Chang, Jin Woo Kim, Siqun Lilly Zheng, William B Isaacs, Jianfeng Xu.   

Abstract

BACKGROUND: Identifying genomic regions that are commonly deleted or gained in neoplastic cells is an important approach to identify tumor suppressor genes and oncogenes. Studies in the last two decades have identified a number of common DNA copy number alterations in prostate cancer. However, because of various sample sizes, diverse tumor types and sources, as well as a variety of detection methods with various sensitivities and resolutions, it is difficult to summarize and fully interpret the overall results.
METHODS: We performed a combined analysis of all published comparative genomic hybridization (CGH) studies of prostate cancer and estimated the frequency of alterations across the genome for all tumors, as well as in advanced and localized tumors separately. A total of 41 studies examining 872 cancers were included in this study.
RESULTS: The frequency of deletions and gains were estimated in all tumors, as well as in advanced and localized tumors. Eight deleted and five gained regions were found in more than 10% of the prostate tumors. An additional six regions were commonly deleted and seven were commonly gained in advanced tumors. While 8p was the most common location of deletion, occurring in about a third of all tumors and about half of advanced tumors, 8q was the most commonly gained region, affecting about a quarter of all tumors and about half of all advanced tumors.
CONCLUSIONS: The large number of tumors examined in this combined analysis provides better estimates of the frequency of specific alterations in the prostate cancer cell genome, and offers important clues for prioritizing efforts to identify tumor suppressor genes and oncogenes in these altered regions. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17342750     DOI: 10.1002/pros.20543

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  68 in total

1.  The effect of CXCL9 on the invasion ability of hepatocellular carcinoma through up-regulation of PREX2.

Authors:  Xiaoqin Lan; Fang Xiao; Qiang Ding; Jiqiao Liu; Jingmei Liu; Junhua Li; Jiong Zhang; De-An Tian
Journal:  J Mol Histol       Date:  2014-08-24       Impact factor: 2.611

Review 2.  Molecular alterations in prostate cancer as diagnostic, prognostic, and therapeutic targets.

Authors:  Bora Gurel; Tsuyoshi Iwata; Cheryl M Koh; Srinivasan Yegnasubramanian; William G Nelson; Angelo M De Marzo
Journal:  Adv Anat Pathol       Date:  2008-11       Impact factor: 3.875

3.  Cells Comprising the Prostate Cancer Microenvironment Lack Recurrent Clonal Somatic Genomic Aberrations.

Authors:  Daniella Bianchi-Frias; Ryan Basom; Jeffrey J Delrow; Ilsa M Coleman; Olga Dakhova; Xiaoyu Qu; Min Fang; Omar E Franco; Nolan G Ericson; Jason H Bielas; Simon W Hayward; Lawrence True; Colm Morrissey; Lisha Brown; Neil A Bhowmick; David Rowley; Michael Ittmann; Peter S Nelson
Journal:  Mol Cancer Res       Date:  2016-01-11       Impact factor: 5.852

4.  Canine prostate cancer cell line (Probasco) produces osteoblastic metastases in vivo.

Authors:  Jessica K Simmons; Wessel P Dirksen; Blake E Hildreth; Carlee Dorr; Christina Williams; Rachael Thomas; Matthew Breen; Ramiro E Toribio; Thomas J Rosol
Journal:  Prostate       Date:  2014-07-07       Impact factor: 4.104

5.  PTEN inhibits PREX2-catalyzed activation of RAC1 to restrain tumor cell invasion.

Authors:  Sarah M Mense; Douglas Barrows; Cindy Hodakoski; Nicole Steinbach; David Schoenfeld; William Su; Benjamin D Hopkins; Tao Su; Barry Fine; Hanina Hibshoosh; Ramon Parsons
Journal:  Sci Signal       Date:  2015-03-31       Impact factor: 8.192

6.  Comparative analyses of chromosome alterations in soft-tissue metastases within and across patients with castration-resistant prostate cancer.

Authors:  Ilona N Holcomb; Janet M Young; Ilsa M Coleman; Keyan Salari; Douglas I Grove; Li Hsu; Lawrence D True; Martine P Roudier; Colm M Morrissey; Celestia S Higano; Peter S Nelson; Robert L Vessella; Barbara J Trask
Journal:  Cancer Res       Date:  2009-09-22       Impact factor: 12.701

7.  Single and multivariate associations of MSR1, ELAC2, and RNASEL with prostate cancer in an ethnic diverse cohort of men.

Authors:  Joke Beuten; Jonathan A L Gelfond; Jennifer L Franke; Stacey Shook; Teresa L Johnson-Pais; Ian M Thompson; Robin J Leach
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-01-19       Impact factor: 4.254

8.  Homozygous deletions and recurrent amplifications implicate new genes involved in prostate cancer.

Authors:  Wennuan Liu; Chunmei Carol Xie; Yi Zhu; Tao Li; Jishan Sun; Yu Cheng; Charles M Ewing; Sue Dalrymple; Aubrey R Turner; Jielin Sun; John T Isaacs; Bao-Li Chang; Siqun Lilly Zheng; William B Isaacs; Jianfeng Xu
Journal:  Neoplasia       Date:  2008-08       Impact factor: 5.715

9.  JAB1/CSN5: a new player in cell cycle control and cancer.

Authors:  Terry J Shackleford; Francois X Claret
Journal:  Cell Div       Date:  2010-10-18       Impact factor: 5.130

10.  Candidate metastasis suppressor genes uncovered by array comparative genomic hybridization in a mouse allograft model of prostate cancer.

Authors:  Yajun Yi; Srinivas Nandana; Thomas Case; Colleen Nelson; Tatjana Radmilovic; Robert J Matusik; Karen D Tsuchiya
Journal:  Mol Cytogenet       Date:  2009-09-26       Impact factor: 2.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.